All News

gout.podagra.jpg

Pegloticase in Severe Refractory Gout

d Olga Petryna, MD

Listen as Dr. Petryna reviews abstracts #0683 (Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate) and #0677 (A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study) from the 2020 ACR meeting. 

Read Article
blackboard chalkboard

SpA: Etiology to Diagnosis to Treatment - An Abstract Roundup

d Robert Chao, MD

Here's a review of ten abstracts and presentations on spondyloarthritis encompassing a wide range of topics from etiology to diagnosis to treatment.  

Read Article
guidelines.recommendations.jpg

New ACR RA Guidelines and Practice Changing Abstracts: RA Panel

d Jonathan Kay, MD

Dr. Jonathan Kay leads an international panel discussion on the new ACR RA guidelines and several practice-changing abstracts presented at the 2020 ACR meeting. Panelists include Dr. Kathryn Dao, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway and Dr. Sheila Reyes.

Read Article
ACR20 Podcast

ACR20 - Autoinflammatory & Still's Disease Panel

d Jack Cush, MD

This podcast features a discussion of autoinflammatory and Still's disease abstracts from virtual ACR 2020. Dr. Jack Cush is joined by a panel of experts including Drs. Olga Petryna, Bella Metha and Michael Ombrello.

Read Article
#BestACR20Tweets RT @ejdein1 : Worth checking out the #ACR20 image competition. Here's an image of cerebral toxoplasmosis during ADA treatment for RA https://t.co/JH07pMjvRe https://t.co/H9LHwiw4xL

Links:

Dr. John Cush RheumNow ( View Tweet)
Auckland-based rheumatologist Dr. Nicola Dalbeth discusses improving responses to the use of Pegloticase, including abstracts #0677 and #0952 presented at #ACR20. https://t.co/xeiMYLZEQa https://t.co/a4RJ6BrNgn

Links:

Dr. John Cush RheumNow ( View Tweet)
Vaccination with Shingrix: Does it work for patients on JAKi? #ACR20 https://t.co/PLWn3SshcI https://t.co/APBcfP1zlH

Links:

Dr. John Cush RheumNow ( View Tweet)
Nomenclature, Uveitis and Other Spondyloarthritis Features with Dr. Lianne Gensler #ACR20 https://t.co/zql7iySXOA https://t.co/PY9k108QTc

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @doctorRBC : Tocilizumab NOT effective in preventing mechanical ventilation or death in moderately ill COVID-19 pts. Double-blind, Placebo, RCT (n=243) @RheumNow #ACR20 Abs#L07 #ACRbest https://t.co/Gi5FpodeKf https://t.co/bTk8n7dNni

Links:

Dr. John Cush RheumNow ( View Tweet)
Warfarin and Risk of Hip and Knee Replacements with Dr. Mrinalini Dey ( @DrMiniDey) #ACR20. https://t.co/znTxIx1QQZ https://t.co/elQlChwr0N

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @KDAO2011 : The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF weren't allowed in this study; still cautious prescribing febuxostat to pts who have severe CVD until we have more data. https://t.co/eyl2kOjEEU https://t.co/qoQDgRifFg

Links:

Dr. John Cush RheumNow ( View Tweet)
Let us know your thoughts on our article titled "Undifferentiated Autoinflammatory Syndrome Called VEXAS" https://t.co/afNK3UuZef #ACR20 https://t.co/fp2sX9w894

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @synovialjoints : Can we find Axial Spa (FaxSpa) using social media? This study used an online screening tool (A-tool) on social media in patients with back pain. 42% had a positive screen and referred for review @RheumNow #ACR20 Abstr#1894

Dr. John Cush RheumNow ( View Tweet)

Dr. Kathryn Dao ( @KDAO2011) reviews abstract #0533 presented at #ACR20 on male osteoporosis. https://t.co/Z0NLcJzslV https://t.co/SSoIA7Eetg

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @DrMiniDey : Late breaking: in older #rheumatoidarthritis patients, those taking MTX have 2x risk of #VTE compared to those on HCQ. Important to consider #thromboembolic risk factors when starting new RA treatment. Abs#2000 #ACR20 https://t.co/lMYlXgaHyE https://t.co/0Fdone9yb3

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @drdavidliew : Mavrilimumab (anti-GM-CSF) in GCA, phase 2 GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying?? PNL induction then enrol+PNL taper GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62% ABSTL06 https://t.co/xxjd2lTSUe https://t.co/uuBOnbk6Ab

Links:

Dr. John Cush RheumNow ( View Tweet)
Did you know we have podcast? Search Rheum Now on Apple/Android or listen directly through the link below. https://t.co/wjBWCrKL34 https://t.co/yhZ2wyujA0

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @synovialjoints : The majority of patients with axSpA were able to use an axSpA smartphone app. recording BASDAI, BASFI 2 weekly. Current disease activity influence adherence to reporting @RheumNow #ACR20 Abstr#1890

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @ejdein1:Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20

Dr. John Cush RheumNow ( View Tweet)

New podcast up! On this episode titled #ACR20 Epilogue, we review more ACR 2020 abstracts and present a new plan to learn or take in ACR20 content. Listen via the link below or download on Apple/Android podcasts. https://t.co/yj1WIcMtfb https://t.co/YjdYpPZNIC

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×